|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| ==Administration==
| | #REDIRECT[[Ribavirin]] |
| *Type: Antiviral- FDA approved for [[Hepatitis C]], severe [[RSV]] infection. Off-label use: [[herpes simplex]], [[influenza]], [[viral hemorrhagic fever]]
| |
| *Dosage Forms: 200 tab, 200 cap
| |
| *Routes of Administration: Oral, inhalation
| |
| *Common Trade Names: Copegus, Rebetol, Ribasphere
| |
| | |
| ==Adult Dosing==
| |
| *200-1000mg daily (dose depends on genotype and concurrent treatment with interferon)
| |
| | |
| ==Pediatric Dosing==
| |
| *Hep C: >2 years old: 15mg/kg daily OR 400-1200mg daily
| |
| *RSV (severe cases): 20mg/ml aerosolized over 12-18 hours x 3-7 days
| |
| | |
| ==Special Populations==
| |
| *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: X
| |
| *[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out
| |
| *Renal dosing: reduced doses for mild-moderate impairment, do not use if CrCl <50
| |
| | |
| ==Contraindications==
| |
| *Allergy to class/drug
| |
| *[[Autoimmune hepatitis]]
| |
| *Coadministration with didanosine
| |
| *Hemoglobinopathy (e.g. [[thalassemia]], [[sickle cell]])
| |
| *[[Pregnant]] or potentially pregnant women, men who may impregnate someone
| |
| *Renal impairment (CrCl <50)
| |
| | |
| ==Adverse Reactions==
| |
| ===Serious===
| |
| *Hemolytic anemia, TTP
| |
| *Bacterial disease
| |
| *Hepatotoxicity
| |
| *MI
| |
| *Suicide
| |
| ===Common===
| |
| *Neutropenia
| |
| *Nausea, vomiting, diarrhea
| |
| *Asthenia, dizziness, fatigue
| |
| *Weight loss
| |
| *Pruritus
| |
| | |
| ==Pharmacology==
| |
| *Half-life: ~300 hours
| |
| *Metabolism:
| |
| *Excretion: Mostly renal
| |
| | |
| ==Mechanism of Action==
| |
| *Mechanism not well understood
| |
| | |
| ==Comments==
| |
| | |
| ==See Also==
| |
| *[[Viral hepatitis]]
| |
| *[[Hepatitis C]]
| |
| | |
| ==References==
| |
| <references/>
| |
| [[Category:Pharmacology]]
| |
